Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Cetrelimab by Johnson & Johnson for Hepatitis B: Likelihood of Approval
Cetrelimab is under clinical development by Johnson & Johnson and currently in Phase I for Hepatitis B. According to GlobalData,...
Data Insights
Cetrelimab by Johnson & Johnson for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Cetrelimab is under clinical development by Johnson & Johnson and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC)....